The FORS awakens: review of a blood group system reborn by Hult, Annika K. & Olsson, Martin L.
64 IMMUNOHEMATOLOGY, Volume 33, Number 2, 2017
The FORS awakens: review of a blood group 
system reborn
A.K. Hult and M.L. Olsson
Revie w
The presence of the FORS1 antigen on red blood cells was 
discovered relatively recently, and in 2012, the International 
Society of Blood Transfusion (ISBT) acknowledged FORS as 
blood group system number 031. This rare antigen is carried by 
a glycosphingolipid and formed by elongation of the P antigen. 
Most people have naturally occurring anti-FORS1 in their plasma. 
The clinical significance of these antibodies is unknown in the 
transfusion setting, but they can hemolyze FORS1+ erythrocytes 
in the presence of complement in vitro. First believed to be part 
of the ABO system, it was later shown that the gene encoding the 
glycosyltransferase giving rise to FORS1 expression is GBGT1. 
This gene had previously been deemed nonfunctional in humans, 
but a mutation, so far only detected in FORS1+ individuals, 
restores the enzymatic activity. Tissue distribution of the antigen 
in FORS1+ individuals has not been studied in detail, although 
the gene is expressed in several cell types. The antigen itself is 
known to be a receptor for various pathogens and toxins and has 
been detected in different forms of cancer, but the implications 
thereof are not fully understood. Immunohematology 
2017;33:64–72.
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The first blood group system was discovered in 1900 
by Landsteiner,1,2 and its antigens were later characterized 
as glycans.3,4 Since then, ABO has been joined by six other 
systems that are also of carbohydrate nature: P1PK, H, 
Lewis, I, GLOB, and FORS (www.isbt-web.org). The defining 
antigens in these blood group systems are all determined 
by immunodominant sugar moieties of glycoproteins 
and/or glycosphingolipids. The function of these structures is 
unknown, but it has been suggested that they are a part of our 
innate immune defense.5 Carbohydrate expression is relatively 
well conserved in mammals, but the variation seen both within 
and between species may reflect evolutionary developments 
to differentiate the individual species-specific susceptibility 
to various pathogens.6 Another common principle for these 
blood group systems is that naturally occurring antibodies 
are formed against the carbohydrate antigens that are lacking. 
These antibodies have the potential to neutralize pathogens 
expressing the corresponding glycan epitopes.7,8 In modern 
medicine, however, they mainly constitute a significant 
transfusion and transplantation barrier and can also cause 
fetomaternal incompatibility. This review will summarize the 
current knowledge on the newest of our carbohydrate blood 
group systems, FORS, acknowledged by the International 
Society of Blood Transfusion (ISBT) in 2012. For obvious 
reasons, the body of knowledge is still limited, especially when 
it comes to the clinical significance of this system.
Forssman: Historical Aspects
The first mention of what was later designated the 
Forssman (Fs) antigen was reported in 1907 by Frouin.9 
This heterophilic antigen was re-identified in 1911 by John 
Forssman (1868–1947), professor of microbiology, pathology, 
and general medicine at Lund University, Lund, Sweden 
(Fig. 1). He immunized rabbits with tissue from guinea pig 
or horse, and these rabbits produced an antibody that was 
shown to hemolyze red blood cells (RBCs) from sheep in the 
presence of complement. Tissue from other species (e.g., cow 
or rat) did not induce the same immune response.10 In honor 
of his detailed description of these experiments, the antigen 
recognized by these antisera was named after Dr. Forssman.
By using the antibodies towards this (then structurally 
undefined) antigen, different animal species were categorized 
to be either Fs+ or Fs–.11 Humans were defined as an Fs– 
species, although there are reports claiming the presence of 
this structure in human tissue from malignant tumors12–17 and 
even a few publications on its presence in normal tissue.12,18
Fig. 1 Dr. John Forssman, professor of 
pathology, microbiology, and general 
medicine at Lund University, Lund, 
Sweden. (Image source: The South 
Swedish Society for the History of 
Medicine.)
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The Fs antigen is a carbohydrate moiety present in various 
tissues, including RBCs, depending on species. The structure 
of the antigen was resolved some 60 years after Dr. Forssman’s 
experiments and identified to be GalNAcα1-3GalNAcβ1-
3Galα1-4Galβ1-4Glcβ1-Cer by Siddiqui and Hakomori.19 
A few years later, the structure was confirmed by mass 
spectrometry.20
Over the years, the naturally occurring antibodies 
towards Fs present in the vast majority of people have 
been associated with different autoimmune diseases such 
as rheumatoid arthritis,21 Guillain-Barré syndrome,22 and 
Graves’ disease.23 The significance of these findings is still 
unclear. In recent years, anti-Fs has been reported to play a 
role in the xenotransplantation setting.24–26
Nomenclature
In light of recent developments, a motion was made to 
make FORS the 31st blood group system, and this proposal 
was accepted by the ISBT Working Party for Red Cell 
Immunogenetics and Blood Group Terminology at its meeting 
in 2012.27 FORS1 (031001) is so far the only antigen of the 
FORS blood group system. The correct nomenclature is shown 
in Table 1.
Transition from ABO to FORS
The history of the human FORS1 antigen on RBCs 
originates back to 1987 when Dr. Robert Stamps and co-
workers reported what appeared to be a peculiar weak A 
subgroup that they termed Apae. This phenotype was present 
in healthy individuals from three different unrelated English 
families.28 The “p” in Apae stands for the reaction observed 
with Helix pomatia, and “ae” identifies its ability to adsorb 
and elute some polyclonal anti-A reagents. For a long time, the 
antigen underlying this phenotype was considered to be one of 
the many Aweak variants within the ABO blood group system 
(ISBT no. 001) and, as stated in a textbook (“Had the authors 
chosen to call Apae a form of Ax it is doubtful that many would 
have argued”), it was considered very similar to one of the less 
uncommon ABO subgroup phenotypes, Ax.29
Genomic typing of ABO was performed in our laboratory 
on samples from two unrelated individuals displaying the Apae 
phenotype. The purpose was to characterize the underlying A 
allele that caused the hypothesized weak expression of A. The 
surprising result was that both individuals were homozygous 
for the common deletion, c.261delG, in the most frequent O 
alleles (ABO*O.01.01/*O.01.01 and ABO*O.01.01/*O.01.02) 
and should clearly phenotype as group O. Based on this result 
and in collaboration with Professor Steve Henry in Auckland, 
New Zealand, and scientists at the University of Gothenburg in 
Sweden, we subsequently came up with the hypothesis that the 
Apae phenotype must be due to an A-like but ABO-independent 
antigen. In 2013, we published the biochemical and genetic 
characterization of the new blood group.30 We showed that the 
gene that gives rise to the Apae phenotype was indeed not ABO 
but GBGT1 (globoside α-N-acetylgalactosaminyltransferase, 
EC 2.4.1.88), the Forssman gene. Based on the data from that 
report, which included extensive serologic testing, structural 
analysis of the glycolipid antigen, and transfection studies, all 
the data were in place to promote Apae to become the new blood 
group system FORS. The phenotype name Apae was deemed 
obsolete, and the antigen was accordingly named FORS1.
Biochemistry
FORS1 is a glycosphingolipid that is part of the globo-
series synthesis pathway. This pathway also harbors other 
carbohydrate blood group antigens such as Pk, P, NOR, LKE, 
and the globo version (type 4) of H, A, and B. Depending 
on the sugar moiety added to lactosylceramide, different 
glycosphingolipid pathways are created. The globo-series is 
initiated by addition of a galactose (Gal) in the α1–4 position to 
lactosylceramide, and this structure constitutes the Pk antigen 
(also known as globotriaosylceramide, Gb3, or CD77). Adding 
an N-acetyl-d-galactosamine (GalNAc) in a ß1–3 position 
to the Pk structure will result in the P antigen (globoside, 
Gb4), and this structure is the precursor for the enzyme that 
makes FORS1, the Fs synthase (Fig. 2). It has been suggested 
that the Fs antigen may also occur as the glycan portion of 
glycoproteins, but this has not yet been corroborated in 
humans.16,31
The Fs synthase has a topology that matches well 
with the structure of a single-pass type II transmembrane 
glycosyltransferase. In analogy with the blood group A 
transferase, 3-α-N-acetylgalactosaminyltransferase (GTA), 
the Fs synthase transfers a terminal GalNAc in α1–3 linkage. 
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Table 1. Summary and nomenclature of the FORS blood group 
system
System name FORS (ISBT no. 031)
System symbol FORS
Antigen name FORS1 (ISBT no. 031001)
Carrier molecule Forssman glycosphingolipid
Synthesized by Forssman synthase
Gene name GBGT1
ISBT = International Society of Blood Transfusion.
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Instead of the H antigen, however, the required precursor for 
Fs synthase is the P antigen (globoside, Gb4), as mentioned 
earlier (Fig. 3).
Based on sequence similarities, glycosyltransferases have 
been categorized into families in the Carbohydrate-Active 
EnZymes (CAZy) database.32 The Fs synthase is encoded by 
the GBGT1 gene and belongs to the GlycosylTransferase 6 
(GT6) family alongside, for example, ABO (Table 2).
Until the discovery of FORS1+ individuals, GTA and 
3-α-galactosyltransferase (GTB)—responsible for blood group 
A and B expression,33 respectively—were considered to be 
the only functional glycosyltransferases in the human GT6 
family. The other members (Table 2) had been deemed 
nonfunctional.30,34–37 The number of GT6 genes varies from 
species to species, and even within phylogenetic groups, the 
type and number of genes can vary significantly.39
Genetic and Molecular Basis
The sequence homology between the members of the GT6 
family indicates that these genes were derived from the same 
ancestral gene where gene duplications have occurred with 
subsequent divergence. The expansion and deletions of GT6 
genes during vertebrate evolution suggests that this multigene 
family follows a birth-and-death evolution type.39,40
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Fig. 2 Synthetic pathway for the glycosphingolipid constituting 
the FORS1 blood group antigen (black box) as well as schematic 
representation of other related structures (white and gray boxes) of 
the globo-series (right) and neolacto-series (left). ABO antigens are 
shown in dark gray; other blood group antigens are shown in light 
gray. For the globo-series pathway resulting in the FORS1 antigen, 
the responsible genes are given in parentheses under the implicated 
enzymes.
Fig. 3 The FORS1 antigen and its precursor, the P blood group 
antigen (also known as globoside, Gb4), are shown schematically 
in comparison with blood group A antigen synthesis by A 
glycosyltransferase (GTA), where the H antigen is the required 
precursor.
Table 2. Details about the most investigated members of the human GlycosylTransferase 6 (GT6) gene family
EC no. Glycosyltransferase Donor Acceptor Gene
Chromosome 
location Transcribed Translated Produced antigen Reference





H antigen ABO 9q34 Yes Yes A 33
2.4.1.87 3-α-galactosyltransferase UDP-Gal Galβ1-
4GlcNAc-R
GGTA1 9q33 Yes No α-Gal epitope 34
35
2.4.1.87 3-α-galactosyltransferase UDP-Gal Galβ1-4Glcβ1-
Cer








GBGT1 9q34 Yes No/Yes Forssman 30
37
38
EC no. = enzyme commission number.
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The cDNA corresponding to the canine Fs synthase was 
cloned in 1996 by Haslam and Baenziger.41 A 347–amino 
acid (aa) open reading frame (ORF) was predicted, and as 
previously mentioned, the overall structure matches well with 
a type II transmembrane glycosyltransferase. The canine Fs 
synthase construct was tested in a transfection experiment 
where it was shown to result in expression of the Fs antigen in 
the COS-1 cell line.
The human GBGT1 equivalent was cloned in 1999 by Xu 
et al.37 It is situated on chromosome 9 (9q34) in close proximity 
to the ABO gene and consists of seven exons spanning over 
~11 kb (Fig. 4). The human aa sequence showed a 45 percent 
homology to GTA and GTB.33,36 The ORF (1041 nucleotides 
[nts]) encodes a 347-aa-long protein with a molecular 
weight of ~40 kDa. In that study, the authors also showed 
by transfection studies that the human Fs synthase did not 
possess the ability to synthesize Fs glycolipid, as the canine 
version did. This finding corroborated the known expression 
of Fs in dogs and its absence in humans. Chimeric constructs, 
namely, combinations of canine and human sequences, 
showed that the human catalytic site was inactive, but no 
precise reason as to why was proposed. RNA expression in a 
variety of tissues was measured, and transcripts were detected 
in all tissues examined but did not appear to give rise to Fs 
antigen expression. The authors hypothesized that, given the 
high expression of RNA, this human Fs synthase might have 
acquired an altered enzyme specificity. Others have argued that 
the high homology with canine Fs synthase and the presence 
of transcripts suggest that the human ability to synthesize Fs 
was lost quite recently in an evolutionary perspective.42
Svensson et al.30 reported the first verified and structurally 
confirmed expression of the Fs antigen on human RBCs. In 
addition to extensive serological and biochemical verification 
of the antigen, it was shown that individuals with the Apae 
phenotype had a single nucleotide polymorphism (SNP) in 
the ORF of the GBGT1 gene. The mutation c.887G>A gave rise 
to an aa change, p.Arg296Gln, and we hypothesized that this 
was the key residue for the gain of function for the Fs synthase 
in these individuals. This idea was supported by genetic 
analysis of available members in the family pedigrees and also 
confirmed by transfection of Fs– cell lines that became Fs+ 
when 887A but not 887G Fs synthase-encoding constructs 
were introduced.30 The same finding, but from a different angle, 
was simultaneously corroborated in a study by Yamamoto et 
al.,38 in which they showed aa position 296 to be essential for 
Fs antigen expression. This was hypothesized by comparing 
aa sequences of Fs– and Fs+ species, thereby identifying 
candidate aa positions in the enzyme conserved in Fs+ species 
and differing from Fs– species. This approach revealed 
three positions for further testing: c.536C>T (p.Ile179Thr), 
c.688G>A (p.Gly230Ser), and c.887A>G (p.Gln296Arg). Each 
of these substitutions was evaluated by introducing them into a 
mouse Fs construct (an Fs+ species) for subsequent expression 
in the COS-1 cell line. Two positions were shown to be crucial 
for Fs antigen expression, when changing nts c.688 and 
c.887 to the murine equivalent in a human construct, the Fs 
synthase activity was completely restored to allow synthesis 
of Fs antigen in the COS-1 cell line. The conclusion drawn was 
that p.Ser230Gly and p.Gln296Arg constitute the cause of Fs 
negativity in humans, although the study by Svensson et al.30 
showed that p.Arg296Gln suffices for RBC expression of Fs 
activity.
The prevalence of c.887G>A is very low, less than 1 
percent in the populations tested, but c.887G>A has been 
detected on two distinct alleles in different families. In 
addition to the investigated pedigrees from Stamps et al.,28 
the mutation has also been found in a database search in the 
NHLBI-ESP (National Heart, Lung, and Blood Institute–
Exome Sequencing Project),43 although the phenotype has 
not been confirmed there. A mutation, c.363C>A, that gives 
rise to an early stop codon in exon 7 truncates the Fs synthase 
prematurely and is predicted to cause lack of the enzymatic 
site. This null allele is fairly common and shows a prevalence 
of greater than 4 percent according to the Erythrogene 
database (www.erythrogene.com), an open Web resource that 
summarizes the allelic variation in all blood group genes in the 
2504 individuals (from 26 different populations around the 
globe) included in the 1000 Genomes Project.44 Multiple other 
GBGT1 variants were observed in this database but, for most, 
their prevalence is very low. Among the 68 GBGT1 alleles noted 
in Erythrogene so far, only 4 have an allele frequency greater 
than 1 percent, and 32 were found only once and may need 
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Fig. 4 Genomic organization of the GBGT1 gene. The seven exons are represented by numbered rectangles drawn to scale (introns, 
represented by a gray line, are not). Black vertical lines in exons 2 and 7 indicate the start and stop codons, respectively, and the open reading 
frame is shown in dark gray.
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confirmation. In fact, the two alleles that give rise to FORS1 
were not found at all in the 1000 Genomes samples but are 
included only in the ISBT reference lists (www.isbt-web.org).
Antigens and Antibodies in the System
Antigens
Because FORS1+ is very rare, its real prevalence is 
unknown, but so far only three families with the Apae 
phenotype (now referred to as FORS1+) have been reported. 
In addition, a single individual with the same genetic variant 
has been noted, but no phenotypic data were available. So far, 
the antigen has only been detected in individuals of European 
extraction. The Fs glycosphingolipid structure is normally not 
expressed on any type of human tissue and is widely regarded 
as a structure only found in certain animal species. Because 
screening for FORS1 is not a standard procedure, it is unlikely 
to detect this rare phenotype on a routine basis. Nevertheless, 
if detection of c.887G>A were to be integrated on commercially 
available genotyping platforms in the future, screening could 
easily become part of daily practice. A possible reason to do this 
would be to rid blood banks of donated RBC units expressing 
FORS1. This may become an issue of debate if the naturally 
occurring antibodies against FORS1 (discussed in the next 
section) found in the plasma of most people were found to be 
clinically significant—that is, hemolytic in vivo.
In the original report by Stamps et al.,28 the Apae 
phenotype was detected by a cross-reaction of a polyclonal 
anti-A, but because polyclonal ABO reagents are scarce 
today and standard ABO phenotyping is now performed 
with monoclonal reagents, detecting this rare phenotype by 
ABO typing is unlikely. In a study by Barr et al.,45 the authors 
tested 19 monoclonal anti-A reagents against kodecytes, RBCs 
uploaded with a FORS1 pentasaccharide Function-Spacer-
Lipid (FSL) construct,46 and did not notice any of the cross-
reactivity seen with polyclonal reagents.
Antibodies
In analogy with ABO, most humans have naturally 
occurring antibodies to the FORS1 antigen they lack. These 
antibodies are believed to be formed in response to microbial 
surface glycan structures in the commensal gut flora, because 
some of the latter are very similar to carbohydrate blood 
group antigens. Their presence may be a microbial strategy to 
evade the immune defense in the host in accordance with the 
molecular mimicry concept.47 The human anti-Fs are mainly 
of IgM type, but there may also be a component of IgG.48,49 
Svensson et al.30 reported crossmatch reactivity with FORS1+ 
RBCs to be about 6 percent by the indirect antiglobulin test, 
and approximately 23 percent caused direct agglutination. 
Great variation in antibody strength was seen among the 
almost 300 samples of random blood donor plasmas tested.
In a recent screening study, which included 800 blood 
donors, it was shown that all plasma samples but one had 
antibodies against sheep RBCs, which are known to express 
very high levels of the Forssman antigen. These donor plasma 
samples also reacted with kodecytes.50 The possible influence 
of other human anti-sheep xenoantibodies as reported by 
Strokan et al.49 and potential cross-reactions of the polyclonal 
anti-A present in human plasma were not discussed in that 
report.
The clinical relevance of anti-FORS1 in a transfusion 
setting remains unclear, but it has been shown that human 
ABO-compatible plasma has the ability to hemolyze FORS1+ 
RBCs in the presence of complement. This finding is further 
emphasized when RBCs have been papainized.30 From a 
transfusion point of view, FORS1+ units should only be 
transfused following a negative crossmatch until we know 
more (i.e., electronic crossmatch using type-and-screen 
should not be used).30 The electronic crossmatch is currently 
used in many parts of the world; thus, a FORS1+ unit may 
be 4+ incompatible and still be transfused. Because of the low 
prevalence of this phenotype, it is still questionable whether 
genetic screening to exclude FORS1+ donors is worthwhile.
Tissue Distribution
The heterophilic Fs antigen has been recognized in several 
species, both mammals and others. Because it is expressed in 
some species, but not in others, the presence or absence of the 
Fs antigen has classified species as Fs+ or Fs–.11 Sheep, dog, 
cat, and mouse are examples of Fs+ animals, whereas pigeon, 
rabbit, cow, and rat do not express the Fs antigen. The level 
of antigen seen on RBCs varies; some are high expressers, 
like sheep RBCs, with lower expression seen on RBCs from 
dogs and cats. There is also heterogeneity with respect to 
what cell types carry the antigen; in many species, Fs antigen 
expression is not found on RBCs but is restricted to other 
tissue. Purification of the Fs glycolipid from different species 
has been performed from kidney tissue and intestinal mucosa, 
among others.20,31 Humans and apes have been considered 
Fs–, but there are some reports of Fs glycolipid expression in 
normal human non-hematopoietic tissue.12,16,18 Because the Fs 
synthase has been deemed nonfunctional in the majority of 
humans, the mechanism underlying this expression remains 
unknown.
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Although the expression of Fs antigen on human RBCs 
was unequivocally shown by Svensson et al.,30 the presence of 
the antigen in non-erythroid tissue in these individuals was 
not investigated. It has been shown that the GBGT1 gene is 
transcribed in different human tissues,37 but this finding is not 
expected to give rise to any Fs antigen expression in FORS1– 
individuals. It is tantalizing, therefore, to speculate that an 
individual expressing the antigen on RBCs may express the 
antigen in other tissues as well, since other antigens in the 
globo-series like P and Pk are expressed, for example, in the 
urinary tract. The mRNA levels as measured in blood did not 
show any significant difference between FORS1+ individuals 
and FORS1– controls, but the c.887G>A-activated version 
of the GBGT1 gene is able to give rise to significant levels 
of FORS1 on RBCs. This finding begs the question in these 
FORS1+ individuals: Is the Fs glycosphingolipid expressed 
in all the various tissues where the gene is transcribed? Post-
transcriptional and epigenetic factors may of course influence 
this, and so does the availability of acceptor substrate for the 
translated enzyme. Another major question that remains to be 
answered is how is this gene regulated.
Disease Associations
Infections
The first type of structures that many pathogens encounter 
in the host are glycans on cell surfaces and in mucus. There 
are numerous examples of bacteria, viruses, and parasites 
that invade/impact the host cells via these carbohydrate 
structures, some of them being blood group antigens. For 
example, Helicobacter pylori, known to cause gastritis, uses 
the Leb antigen,51 and the norovirus that causes gastroenteritis 
is dependent on the ABO secretor status of the host.52,53 In the 
most virulent species of the malaria parasite, Plasmodium 
falciparum, it has been shown that the parasite-rosetting 
ligands PfEMP1 and RIFINs bind to RBC surface structures 
including CR1 and A antigens, respectively. For instance, 
when infected RBCs form rosettes with uninfected RBCs in 
a group A individual, the rosettes are bigger and not as easily 
disrupted as the ones formed in group O individuals. In fact, 
the latter interaction may be the reason why blood group O 
protects against severe outcomes from cerebral malaria.54–57 
Currently, however, there is no human disease that shows 
a clear association with the FORS1+ phenotype, possibly 
because such individuals have only recently been identified.
The expression of different carbohydrate structures may 
determine host tropism to microorganisms and, as with many 
other antigens, the Fs structure can act as an involuntary 
receptor for microbes. Xu et al.37 used a canine GBGT1 
construct for transfection experiments and expressed the Fs 
antigen in either a human or a primate cell line. Following 
transfection, canine uropathogenic Escherichia coli were able 
to bind the Fs-expressing cells but not the wild-type mock-
transfected cells.37
P-fimbriated E. coli strains may express papG or prsG 
adhesins, which recognize blood group structures. Whereas 
papG prefers the Galα4Gal motif in glycolipids like P1 and 
Pk antigens, the prsG adhesion binds to the Fs-terminating 
structure GalNAcα3GalNAc.58 It has also been shown that 
prsG+ E. coli can agglutinate RBCs from FORS1+ individuals 
and from sheep but not control RBCs from healthy blood 
donors, independent of ABO group.30 The clinical consequence 
of this is not clear but proposes a potential for trans-species 
infections to occur if the Fs antigen is present on urinary tract 
epithelium, as many of the related glycolipids are.
Expressing the Fs antigen can also protect the host in 
some scenarios. The susceptibility to Shiga toxin (Stx) 1 is 
lowered because the preferred binding site (the P antigen, Gb4) 
is converted into the Fs antigen.42 On the other hand, Stx2e 
isolates from pigs and humans showed a clear interaction with 
the Fs glycosphingolipid in another study, whereas Stx1 and 
Stx2 did not.59
Cancer
The complex role of glycosylation in cancer is widely 
acknowledged but not fully understood. Glycosylation 
alterations such as over- and underexpression and aberrant 
expression is associated with oncogenic transformation.60 
The COSMIC (Catalogue of Somatic Mutations in Cancer) 
database61 lists 66 mutations found in the GBGT1 gene in 
relation to various forms of malignancies. There are a number 
of reports of the Fs antigen being expressed in different forms 
of cancer and malignant tumor tissue,12–17 but the mechanism 
behind this expression is still to be elucidated. Interestingly, 
Hakomori et al.12 reported that when the Fs glycolipid was 
detected in malignant tissue, the surrounding normal tissue 
typed Fs–; conversely, when present in normal tissue, the Fs 
glycolipid was not detectable in tumor tissue. The authors also 
suggested that the incompatible A-like antigen seen in some 
tumors in non-A individuals may instead be the Fs antigen.12
The mechanisms behind this enigmatic expression of the 
Fs antigen are yet to be resolved, and there are many aspects 
to take into consideration. In an interesting study from 2017, 
Yamamoto et al.62 showed that other glycosyltransferases can 
be pushed to synthesize the Fs antigen in the laboratory setting 
based on artificial (not naturally occurring) recombinant 
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glycosyltransferases. In a situation like cancer, where genetic 
events are not as closely surveilled and corrected, mechanisms 
like this may interact with other factors that need to be further 
examined, such as aberrations in splicing, post-translational 
modification of the protein, various epigenetic factors, and so 
forth. As an example of this, Jacob et al.63 showed that GBGT1 
expression in ovarian cancer cells could be epigenetically 
downregulated through hypermethylation of the promoter, 
and this finding was also correlated to protein, Fs synthase, 
expression.
Summary
The FORS blood group system is young in the context of 
transfusion medicine. Nevertheless, its single antigen, FORS1, 
and its corresponding antibody specificity have played a 
role in medicine for more than a century. The presence and 
significance of FORS1 in non-erythroid human tissue is still 
under debate, both in health and disease. The rare FORS1+ 
RBC phenotype is important to bear in mind when running 
into unexpected results with lectins and in ABO discrepancies, 
especially because most people have naturally occurring anti-
FORS1 in their plasma. Solving the biochemical and genetic 
basis underlying human FORS1 expression has added valuable 
information to our knowledge base about carbohydrate blood 
group antigens.
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